The biotech company Biovica has, based on the authorization given by the extraordinary general meeting, resolved to carry out a directed new share issue of Class B shares to institutional investors in the Nordics and Europe.

Through the directed new share issue, Biovica will raise SEK 60 million before transaction costs. Biovica intends to use the proceeds to primarily finance the preparations for the application to the FDA regarding approval for the US market and to obtain compensation for DiviTum® - a test for accurately measuring cell proliferation.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome.

Pareto Securities is financial advisor and Baker McKenzie is legal advisor in connection with the directed new share issue. Baker McKenzie’s team mainly consists of Joakim Falkner, Johanna Flink and Ian Gulam.

Explore Our Newsroom